World's Best Scientists 2026 revealed!
Patrick Schöffski

Patrick Schöffski

D-Index & Metrics

Medicine

D-Index
101
Citations
49767
World Ranking
7839
National Ranking
90

Overview

Patrick Schöffski is affiliated with KU Leuven in Belgium and has contributed extensively to the field of medicine, with a focus on pulmonary and respiratory medicine, oncology, gastroenterology, surgery, and molecular biology. Their research work spans numerous topics, including sarcoma diagnosis and treatment, gastrointestinal tumor research and treatment, gastric cancer management and outcomes, vascular tumors and angiosarcomas, CAR-T cell therapy research, gastrointestinal disorders and treatments, and cancer immunotherapy and biomarkers.

Frequent co-authors in their publications include Agnieszka Woźniak, Robin L. Jones, Sebastian Bauer, Jean-Yves Blay, and Hans Gelderblom.

Patrick Schöffski has published in several prominent venues, with the most frequent being:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • ESMO Open
  • European Journal of Cancer

Among their recent papers are:

  • Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, 2022, Zurich Open Repository and Archive (University of Zurich)
  • Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Best Publications

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

    Winette T A Van Der Graaf;Jean Yves Blay;Sant P. Chawla;Dong Wan Kim

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Cabozantinib in Progressive Medullary Thyroid Cancer

    Rossella Elisei;Martin J. Schlumberger;Stefan P. Müller;Patrick Schöffski

  • Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

    Ian Judson;Jaap Verweij;Hans Gelderblom;Jörg T Hartmann;Jörg T Hartmann

  • Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

    E. Van Cutsem;H. van de Velde;P. Karasek;H. Oettle

  • Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer―Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

    Stefan Sleijfer;Isabelle Ray-Coquard;Zsuzsa Papai;Axel Le Cesne

  • Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

    Patrick Schöffski;Sant Chawla;Robert G. Maki;Antoine Italiano

  • Biokinetics and imaging with the somatostatin receptor PET radioligand 68 Ga-DOTATOC: preliminary data

    M Hofmann;H Maecke;R Börner;E Weckesser

  • XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer

    Jim Cassidy;Josep Tabernero;Chris Twelves;René Brunet

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

    Manish R. Patel;John Ellerton;Jeffrey R. Infante;Manish Agrawal

  • Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients

    CH Kohne;D Cunningham;F Di Costanzo;B Glimelius

  • Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

    David C. Smith;Matthew R. Smith;Christopher Sweeney;Aymen A. Elfiky

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Jean-Jacques Grob

  • Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;S. Bielack;N. Abecassis;H.T. Aro

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

Frequent Co-Authors

Raf Sciot
Raf Sciot KU Leuven
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Piotr Rutkowski
Piotr Rutkowski Maria Sklodowska-Curie National Research Institute of Oncology
George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Peter Hohenberger
Peter Hohenberger Heidelberg University
Hans Wildiers
Hans Wildiers KU Leuven
Silvia Stacchiotti
Silvia Stacchiotti University of Milan
Robert G. Maki
Robert G. Maki University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are exploring a career in medicine, a range of related online degrees can help broaden your opportunities. Healthcare is a diverse field, and many roles now offer flexible online study options to fit your personal and professional commitments.

For those interested in advanced pharmacy practice, consider reviewing accredited online pharm d programs. These programs prepare you for high-level pharmacy roles and can enhance your clinical expertise.

Careers in healthcare administration and data management are also in demand. Accredited him programs (Health Information Management) provide the skills needed to manage patient information and support clinical care from a data-driven perspective.

If you prefer a non-clinical route, online medical billing and coding certifications are a great way to join the healthcare sector. These programs open doors to roles in medical administration across hospitals, clinics, and insurance companies.

For nurses seeking advancement, the cheapest online acute care nurse practitioner programs combine flexibility with rigorous training, preparing you for leadership in acute and primary care environments.

Best Scientists Citing Patrick Schöffski

Trending Scientists

Recently Published Articles